The Coca-Cola Company 10-Qquarter ended 2026-07-03

Executive Summary

Coca-Cola delivered volume-led growth and higher margins in Q2 2026, with operating income outpacing revenue despite increased marketing investment and commodity costs. Demand expanded across every region, but Asia Pacific’s affordability initiatives and unfavorable product mix prevented strong volume growth from translating into comparable revenue or profit gains. Cash generation recovered sharply, although the comparison benefited substantially from the prior-year fairlife milestone payment rather than operating improvement alone. The investor thesis rests on sustaining profitable demand growth and simplifying bottling ownership, while the potentially substantial IRS liability remains the largest threat to capital allocation.

Key Financial Highlights

• Cash conversion: H1 OCF reversed a $(1.39)B prior-year outflow; the comparison included the $6.07B fairlife final milestone payment in H1 2025. Current-period operating assets and liabilities consumed $1.27B; receivables factoring of $7.01B also supported reported operating cash flow.
• Capital return: dividends paid totaled $4.56B and repurchases $549M, but shares outstanding increased slightly to 4.303B from 4.302B. Buybacks offset employee issuance rather than shrinking the share count.
• Earnings quality: H1 securities gains contributed $301M. Separately, revised African bottling disposal estimates reversed $56M of impairment in H1, including $66M in Q2; this was an accounting estimate change, not operating improvement.
• Liquidity: cash, short-term investments and marketable securities totaled $16.4B, supplemented by $6.6B of unused backup credit lines. H1 capital expenditures were $684M; management expects ≈$2.2B for FY 2026, implying heavier investment later in the year.

Business Developments

• Demand and marketing: worldwide unit case volume increased 5% in Q2 and 4% in H1, while H1 advertising spending rose 22% to $2.94B. Concentrate shipments benefited from timing and six additional Q1 days; management expects FY concentrate growth slightly below unit case growth.
• Regional economics: Asia Pacific Q2 volume rose 8%, but revenue increased only 1% as price/mix reduced growth by nine percentage points. Latin America revenue grew 16%, with 11 percentage points from currency, making its reported acceleration less representative of underlying demand.
• Bottling simplification: the planned African bottling sale to Coca-Cola HBC is subject to regulatory approval, with closing expected by year-end 2026 and subsequent deconsolidation. Held-for-sale assets of $5.44B and associated liabilities of $2.44B indicate a meaningful balance-sheet transition; recent India refranchising and Nigeria divestiture also affect comparisons.

Risk Assessment

• Tax litigation: the IRS methodology implies ≈$14B of potential incremental tax and interest for 2010–2025, with another $900M added in H1 2026; an adverse appeal outcome could impair recovery of the $6.0B payment and constrain future capital returns.
• Brand valuation: BodyArmor’s $2.44B trademark carrying value approximated fair value after a $960M impairment in Q4 2025, leaving little cushion against weaker performance or higher discount rates.
• Affordability and input costs: Asia Pacific H1 operating income fell 6.2% to $1.19B despite volume growth, demonstrating how lower-priced mix, commodities and marketing can dilute growth.
• Currency dependence: foreign exchange lifted operating income 5% in Q2 and 4% in H1; reversal would weaken reported growth despite hedging.
• Production disruption: ransomware temporarily suspended fairlife production; most operations resumed, but recurrence could interrupt supply and sales.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

Strategic Outlook and Investor Actionables

Management is investing in consumer demand while reducing direct bottling ownership. The opportunity is sustained volume growth with better margins and lower operating complexity; the threat is that affordability pressure, vulnerable brand valuations and tax exposure absorb those benefits.

• Asia Pacific conversion: Q2 volume growth of 8% produced only 1% revenue growth. Later filings should show whether price/mix stabilizes and operating income recovers, or affordability initiatives continue sacrificing profitability.
• BodyArmor recovery: the $2.44B trademark valuation has little headroom. Sustaining its carrying value would support management’s expectations; another impairment would undermine the recovery thesis.
• African refranchising: track management’s expected year-end 2026 closing and deconsolidation against the $5.44B asset base. Completion advances simplification; delays or renewed impairment weaken the expected benefit.
• Tax resolution: follow the appeal heard on 6/25/2026. Recovery of the payment would improve financial flexibility; an adverse ruling and additional liabilities would reduce capacity for investment and shareholder returns.